A preclinical study reports that: LB-100 potentiate standard therapy for provide small cell lung cancer a Strongly rationalefor a Clinical Trial Of LB-100 In Small cell lung cancer recently started.
Application under review as part of US FDA's Real-Time Oncology Review pilot programBased on results of the Phase III IMpower010 study, presented at ASCO, which demonstrated adjuvant: tecentriq improved disease-free.
Written by Lisa Buffington If you've been diagnosed with cancer, you need answers, resources, expertise and reassurance - and you need it now. Because every cancer diagnosis is as unique.
COSELA is the first myeloprotective therapy indicated to reduce the incidence of chemotherapy-induced myelosuppression in adult patients. Credit: G1 Therapeutics. Small cell lung cancer accounts for nearly 10% to 15%.
Most days, if Ross Camidge, MD, PhD, looks around his lung cancer clinic on the University of Colorado Anschutz Medical Campus, a gender difference in his patients is noticeable. Women.
A prompt diagnosis and treatment of cancer can be the difference between life and death. But since 2018, the national average for treating the most urgent suspected cases has fallen.